89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.
Society of Nuclear Medicine and Molecular Imaging (SNMMI) | Strategic Alliance Partners
Latest from Society of Nuclear Medicine and Molecular Imaging (SNMMI)
Advertisement
Advertisement
Trending on CancerNetwork
1
Chlorotoxin-Based Therapy Shows Safety, Feasibility in Glioblastoma
2
Pembrolizumab Regimen May Show Synergy in Melanoma Populations
3
Ezabenlimab Combo Yields Activity in Advanced Squamous Cell Anal Carcinoma
4
Radioembolization Plus Chemotherapy Is Feasible in Liver-Dominant NETs
5
